The Effect of SLC19A3 Inhibition on the Pharmacokinetics of Thiamine

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

7 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-28

Study Completion Date

2023-08-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In Part 1, subjects will be administered thiamine, thiamine with metformin, and thiamine with trimethoprim. Part 2 will expand on Part 1 and subjects will be administered thiamine and thiamine with trimethoprim. The goal is to determine whether taking a drug and a vitamin together affects the body's ability to absorb, distribute, and eliminate thiamine (Vitamin B1).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Thiamine As Adjunctive Therapy for Diabetic Ketoacidosis

NCT03717896

Diabetic Ketoacidosis

COMPLETED PHASE2

Type 2 Diabetes and Blood Brain Barrier Improvement

NCT06322212

Type2diabetes

RECRUITING EARLY_PHASE1

Prevention of Renal Complications of Diabetes With Thiamine

NCT01725412

Diabetic Nephropathy

UNKNOWN PHASE4

Effects of Benfotiamine and AGE on Endothelial Function in People With Diabetes

NCT00437008

Endothelial Dysfunction Type 2 Diabetes Mellitus

COMPLETED PHASE4

Chronic Treatment With Benfotiamine Restores Endothelial Function in People With Type 2 Diabetes Mellitus

NCT00446810

Diabetes Mellitus, Type 2

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Thiamine is an essential vitamin meaning humans must consume thiamine from their diet in order to stay healthy. Low thiamine levels can lead to adverse events. Thiamine is absorbed in the intestine by a transporter protein. This is made by the SLC19A3 gene. The SLC19A3 gene provides instructions for making the thiamine transporter protein, which moves thiamine into cells. Certain drugs, like metformin and trimethoprim, have been shown to interrupt function of the SLC19A3 gene.

Metformin is a first-line therapy for patients with Type 2 diabetes and is associated with improvements in diabetic complications. Trimethoprim is an anti-bacterial drug that is often prescribed to treat infections such as urinary tract infections. At different phases of this study, participants will be administered thiamine, thiamine with metformin, and/or thiamine with trimethoprim to determine whether taking a drug and a vitamin together affects the body's ability to absorb, distribute, and eliminate thiamine. The levels of thiamine in the participants' blood and urine will be measured before and after taking thiamine or thiamine in combination with metformin and/or trimethoprim.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vitamin B1 Deficiency Thiamine Deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Part 1: Three-arm randomized crossover study design Part 2: Two-arm randomized crossover study design

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Thiamine only

5mg thiamine tablet by mouth. This arm will be included in both Parts 1 and 2 of the study.

Group Type ACTIVE_COMPARATOR

Vitamin B1

Intervention Type DIETARY_SUPPLEMENT

5mg of thiamine will be given alone and in combination for both Parts 1 and 2 of the study.

Trimethporim + thiamine combination

5mg thiamine tablet and 300mg trimethoprim tablet by mouth. This arm will be included in both Parts 1 and 2 of the study.

Group Type EXPERIMENTAL

Trimethoprim

Intervention Type DRUG

300mg of trimethoprim will be given in combination with 5mg thiamine and compared to 5mg thiamine only for both Parts 1 and 2 of the study.

Vitamin B1

Intervention Type DIETARY_SUPPLEMENT

5mg of thiamine will be given alone and in combination for both Parts 1 and 2 of the study.

Metformin + thiamine combination

5mg thiamine tablet and 1000mg metformin tablet by mouth. This arm will be included in only Part 1 of the study.

Group Type EXPERIMENTAL

Metformin

Intervention Type DRUG

1000mg of metformin will be given in combination with 5mg thiamine and compared to 5mg thiamine only in Part 1 of the study.

Vitamin B1

Intervention Type DIETARY_SUPPLEMENT

5mg of thiamine will be given alone and in combination for both Parts 1 and 2 of the study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Trimethoprim

300mg of trimethoprim will be given in combination with 5mg thiamine and compared to 5mg thiamine only for both Parts 1 and 2 of the study.

Intervention Type DRUG

Metformin

1000mg of metformin will be given in combination with 5mg thiamine and compared to 5mg thiamine only in Part 1 of the study.

Intervention Type DRUG

Vitamin B1

5mg of thiamine will be given alone and in combination for both Parts 1 and 2 of the study.

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Primsol Glucophage Thiamine

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female between the ages of 18-65 years old.
2. Eats a wide variety of food and willing to consume study diet (i.e. not on a specific diet such as Atkins, Fodmap, etc.).
3. Written informed consent obtained from the subject and ability for subject to comply with the requirements of the study.

Exclusion Criteria

1. Subjects who are pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.
2. Self-reported severe food allergies or diet restrictions (vegans, vegetarians, Atkins, Fodmap, etc.) that would prevent consumption of study diets.
3. Subjects with extreme obesity (BMI \> 35).
4. Subjects who are smokers or have smoked in the past year and/or have smoked or ingested THC/marijuana in the past week, or who are unwilling to comply with a 1-week washout.
5. Subjects with any disease affecting or impairing the function of the liver, kidney or heart.
6. Subjects with moderate to severe hypertension.
7. Subjects with diabetes mellitus, hyperthyroidism, hypothyroidism, cardiovascular disease, glaucoma.
8. Subjects with gastrointestinal disease, gastrointestinal disorder, or gastrointestinal surgery.
9. Subjects with known infection with HIV, Hepatitis B (HBsAg) or Hepatitis C (no laboratory diagnostics concerning these diseases will be performed within the present study. Volunteers who are cured of past HepC infection are eligible to participate with doctor's approval letter).
10. Alcohol use on average \> 2 servings/day or \> 14 servings/wk (Serving size: 12oz beer/4oz wine/2oz hard liquor) or self-reported binge drinking.
11. Subjects that are on vitamin B supplements or multi-vitamins or who have taken vitamin B supplements or multi-vitamins in the past 30 days, or are not willing to comply with a 30-day washout of vitamin B supplements.
12. Subjects with possible folate deficiency.
13. Subjects taking any other clinically significant drugs as judged by the investigator.
14. Subjects with a condition, disease, or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
15. Female subjects undergoing treatment for infertility or hormone replacement therapy (Volunteers using hormonal birth control will not be excluded).
16. Subjects who have taken antimalarials in the past 60 days.
17. Participating in another research study while participating in this research study.
18. Non-English speaking
19. Subjects with abnormal laboratory results at screening as judged by the investigator or study physician.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes